# mTOR and AMPK

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Mechanism
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/mtor-and-ampk-pathways.html

> mTOR and AMPK are the cell's two master metabolic switches: mTOR drives growth and protein synthesis, AMPK drives repair, autophagy and fat burning. The mechanistic evidence is strong and chronic mTOR activation is now classed as a hallmark of aging, but human proof is thin. Rapamycin healthspan data rests on surveys and off-label use, and metformin's lifespan benefit awaits the unfinished TAME trial. The working model is cycling between the two states, not blocking either.

> **Core thesis:** mTOR and AMPK are the two master metabolic switches that determine whether your body is in "growth mode" or "repair mode." mTOR drives building (protein synthesis, cell growth) while AMPK drives repair (autophagy, mitochondrial biogenesis). Health and longevity depend on the rhythmic cycling between these two states — not chronic activation of either.

* * *

## mTOR (Mechanistic Target of Rapamycin)

### Overview

  * **mTORC1:** Sensitive to rapamycin; regulates protein synthesis, lipid synthesis, nucleotide synthesis, and [autophagy](autophagy.html) inhibition
  * **mTORC2:** Less rapamycin-sensitive acutely; regulates cytoskeleton, metabolism, and survival signaling (AKT/SGK1)
  * **Named after:** Rapamycin (sirolimus), the macrolide produced by _Streptomyces hygroscopicus_ that inhibits it



### mTORC1 Activation Signals (updated 2024-2025)

Signal | Source | Effect  
---|---|---  
**Amino acids** (especially leucine, arginine, glutamine) | Dietary protein | Strong activator — Rag GTPase–dependent lysosomal recruitment  
**Insulin/IGF-1** | Carbohydrate/protein intake | Strong activator — IRS1/PI3K/AKT → Rheb  
**Growth factors** | Various hormones | Moderate activator  
**Energy status** (high ATP) | Fed state | Permissive; low ATP releases AMPK-mediated inhibition  
**Oxygen** | Adequate O₂ | Permissive  
**Lysosomal localization** | Ragulator complex on lysosome | Required scaffold — mTORC1 only active when co-localized with Rheb-GTP  
  
**Mechanistic note (2024):** The Rag GTPase–Ragulator–lysosome axis is now recognized as a _coincidence detector_ : mTORC1 activation requires both amino-acid signaling (RagA/B-GTP) and growth-factor signaling (Rheb-GTP) simultaneously, explaining why amino acids alone cannot fully activate mTORC1 in some tissues. PMID [28278478](https://pubmed.ncbi.nlm.nih.gov/28278478/) (Saxton & Sabatini, _Cell_ 2017) remains the canonical reference; recent work (Raghuvanshi et al., 2025; PMID [40933955](https://pubmed.ncbi.nlm.nih.gov/40933955/)) extends this to age-related mTORC1 dysregulation across tissues.

### mTORC1 Downstream Effects

  * **↑ Protein synthesis:** S6K1, 4E-BP1 activation → translation initiation
  * **↑ Lipid synthesis:** SREBP1/2 activation
  * **↓ Autophagy:** ULK1 (Ser757) phosphorylation → autophagy inhibition
  * **↓ Lysosomal biogenesis:** TFEB cytoplasmic sequestration
  * **↑ Nucleotide synthesis:** for DNA/RNA replication
  * **Net effect:** BUILD tissue → appropriate in youth, problematic when chronically active in aging



### mTOR and Aging (2024-2025 update)

  * Chronic mTORC1 activation is now formally classified among the **12 hallmarks of aging** (López-Otín et al., 2023 update)
  * Drives cellular senescence, inhibits autophagy, promotes inflammaging (SASP via 4E-BP1 translational control)
  * Rapamycin is the only drug that **reverses** multiple hallmarks simultaneously in animal models (Raghuvanshi et al., 2025; PMID [40933955](https://pubmed.ncbi.nlm.nih.gov/40933955/))
  * Off-label rapamycin healthspan trials (Kaeberlein 2023, n=333; Mannick survey 2024) report improved self-reported healthspan with low/intermittent dosing — formal placebo-controlled RCTs pending (Hands et al., 2025; PMID [40778880](https://pubmed.ncbi.nlm.nih.gov/40778880/))
  * **Goal is not elimination** but rhythmic cycling — activate for growth (post-exercise), inhibit for repair (fasting, sleep)



* * *

## AMPK (AMP-activated Protein Kinase)

### Overview

  * **Cellular energy sensor:** Activated when AMP:ATP ratio rises (energy depletion)
  * **Master regulator** of catabolic (breakdown) processes
  * **Heterotrimeric structure:** α (catalytic), β (glycogen-sensing scaffold), γ (AMP/ADP/ATP-binding regulatory)
  * **Function:** Shifts cells from anabolic (building) to catabolic (repair) mode



### AMPK Activation Signals

Signal | Source | Effect  
---|---|---  
**High AMP:ATP ratio** | Exercise, fasting, energy depletion | Direct allosteric activator + inhibits dephosphorylation  
**LKB1 kinase** | Upstream kinase | Primary activation pathway in most tissues  
**CaMKK2** | Calcium signaling (muscle contraction) | Activates AMPK independent of AMP  
**Metformin** | Pharmaceutical | Indirect via Complex I inhibition → ↑ AMP  
**Berberine** | Supplement | Similar to metformin  
**Caloric restriction** | Dietary | Energy depletion  
**Exercise** | Physical activity | Energy depletion + LKB1 + CaMKK2  
**Cold exposure** | Temperature stress | Energy expenditure  
  
### AMPK Downstream Effects

  * **↑ Autophagy:** ULK1 (Ser317/Ser777) activation → autophagy initiation (reciprocal to mTOR's Ser757 site)
  * **↑ Mitochondrial biogenesis:** PGC-1α activation → new mitochondria
  * **↑ Fatty acid oxidation:** ACC1/2 inhibition → fat burning
  * **↓ Protein synthesis:** mTORC1 inhibition (via TSC2 activation, Raptor phosphorylation) → reduced building
  * **↓ Gluconeogenesis (hepatic):** Reduced glucose production via FoxO3 / HNF4α
  * **↑ Glucose uptake (muscle):** GLUT4 translocation
  * **↑ SIRT3:** Mitochondrial deacetylase — coordinate with AMPK for oxidative capacity
  * **Net effect:** REPAIR and MAINTAIN → the longevity mode



### AMPK Tissue-Specific Notes (2024-2025)

  * **Skeletal muscle:** PRKAG3 (γ3 isoform) gain-of-function mutations (R225W) provide the only human evidence that chronic AMPK activation increases muscle glycogen and oxidative capacity (Crawford et al., 2010; Kjøbsted et al., 2018, PMID [29236611](https://pubmed.ncbi.nlm.nih.gov/29236611/))
  * **Liver:** AMPK activation suppresses _de novo_ lipogenesis via SREBP1c phosphorylation
  * **Hypothalamus:** AMPK regulates appetite (agouti-related peptide / NPY neurons) — explains why metformin can blunt appetite
  * **Brown adipose:** AMPK activation promotes thermogenic gene expression



* * *

## The See-Saw Model

### The Modern Problem

  * **Chronic mTOR activation:** Constant eating (3-6 meals/day), high protein grazing, high insulin, sarcopenia-anabolic resistance
  * **Insufficient AMPK activation:** Sedentary behavior, constant food availability, no fasting, mitochondrial dysfunction (loss of energetic stress signal)
  * **Result:** Bodies stuck in perpetual growth mode → cancer, obesity, type 2 diabetes, accelerated aging, neurodegeneration



* * *

## mTOR–AMPK Crosstalk (key 2024-2025 evidence)

mTOR and AMPK do not operate in isolation — they directly phosphorylate each other's components:

Node | mTORC1 effect | AMPK effect  
---|---|---  
**ULK1** (autophagy initiator) | Phosphorylates Ser757 → INHIBITS autophagy | Phosphorylates Ser317, Ser777 → ACTIVATES autophagy  
**TSC2** (Rheb GAP) | — (no direct effect) | Phosphorylates → activates TSC2 → inhibits Rheb → inhibits mTORC1  
**Raptor** (mTORC1 subunit) | — | Phosphorylates Ser792 → inhibits mTORC1  
**IRS1** | S6K1 phosphorylates → negative feedback | Protects from degradation → sustained insulin sensitivity  
**ACC** | — | Phosphorylates Ser79 → inhibits fatty acid synthesis, activates oxidation  
  
**Clinical implication:** AMPK activation and mTOR inhibition converge on the same downstream nodes (autophagy, lipid oxidation, protein turnover). This is why metformin (AMPK activator) and rapamycin (mTOR inhibitor) produce overlapping but non-identical effects in longevity trials — they are partial agonists of the same pathway.

* * *

## Practical Pathway Optimization

### To Activate mTOR (Growth — Do Briefly)

  * Resistance training (mechanical tension + leucine → maximal mTORC1)
  * Protein-rich meal (≥2.5g leucine threshold per meal; ~30g total high-quality protein; PMID [16990457](https://pubmed.ncbi.nlm.nih.gov/16990457/))
  * Carbohydrate post-exercise (insulin spike amplifies mTORC1 via AKT)
  * **Timing:** Post-workout window (2-3 hours); specific meals, NOT continuous grazing



### To Activate AMPK (Repair — Do Often)

  * [16+ hour fasting](fasting-approaches.html) windows
  * Zone 2 [exercise](exercise-science-and-longevity.html) in fasted state (CaMKK2 + AMP-dependent)
  * High-intensity interval training (severe ATP depletion)
  * Metformin or berberine (AMPK activation validated in human muscle biopsy studies, PMID [24847808](https://pubmed.ncbi.nlm.nih.gov/24847808/))
  * Cold exposure (BAT activation; muscle CaMKK2 during shivering)
  * Adequate sleep (autophagy peaks in deep sleep)
  * **Timing:** Between meals, overnight, during steady-state exercise



### The Optimal Daily Rhythm

  1. **Morning:** Wake → AMPK active (fasted overnight)
  2. **Train:** Deplete glycogen → more AMPK + CaMKK2
  3. **Post-workout meal:** mTOR activation → muscle protein synthesis peaks at ~2h
  4. **Evening:** Last meal by 6-7pm → mTOR declines, insulin drops
  5. **Night:** AMPK/[autophagy](autophagy.html) peak during deep sleep (growth hormone release)
  6. **Repeat**



### Cyclical Considerations

  * **Age 18-40:** Anabolic sensitivity high — mTOR activation easier, fasting well-tolerated
  * **Age 40-65:** Anabolic resistance emerges — needs higher leucine/protein per meal, longer fasting windows for AMPK benefit
  * **Age 65+:** Sarcopenia risk — mTOR activation via resistance training + protein becomes _more_ important; fasting windows may impair muscle protein synthesis if too aggressive (consider 12-14h not 16h)



* * *

## Drug Interactions with These Pathways (2024-2025)

Intervention | Primary pathway | PMID/key reference  
---|---|---  
**Rapamycin / sirolimus** | mTORC1 inhibition | 37752251 (Peng 2024 systematic review); 37829210 (Johnson 2023)  
**Metformin** | AMPK activation (indirect via Complex I) | 39875425 (Zhang 2025 review); 35165499 (Frontiers 2021)  
**Berberine** | AMPK activation | Comparable to metformin in some markers  
**GLP-1 agonists (semaglutide)** | AMPK activation + mTOR inhibition (via weight loss) | Indirect, mediated by caloric deficit  
**SGLT2 inhibitors** | AMPK activation via nutrient deprivation signaling | PMID: see [SGLT2 Inhibitors as Senotherapeutics](sglt2-inhibitors-as-senotherapeutics-evidence-taxonomy.html)  
**Acarbose** | mTOR attenuation via blunted postprandial glucose/insulin | Life Extension Foundation ITP data  
**Aspirin (low-dose)** | AMPK activation | PMID [23341498](https://pubmed.ncbi.nlm.nih.gov/23341498/)  
  
* * *

## Controversies and Open Questions

  1. **Does metformin extend human lifespan?** TAME trial (Targeting Aging with Metformin) pending; observational data mixed (some replication failures). Mechanistic evidence strong, clinical evidence for lifespan extension in healthy humans remains unproven (Source: Frontiers Endocrinol 2021).
  2. **Optimal rapamycin dose for humans?** Unknown. Off-label use is mostly intermittent and weekly; a 2023 survey of 333 off-label users (Kaeberlein) reported acceptable safety with that pattern, but no trial has compared doses for longevity endpoints.
  3. **Does chronic mTOR inhibition impair muscle hypertrophy?** Concern exists; in practice, intermittent dosing (1-2x/week) appears to avoid anabolic resistance while still conferring healthspan benefits.
  4. **AMPK activation as anti-cancer therapy?** AMPK suppresses Warburg metabolism; AMPK-activating drugs are being explored as senolytics/senostatics, but tumor microenvironment effects are complex (Wang et al., _Cell Death Discov_ 2024).



* * *

## Sources

1. Saxton RA, Sabatini DM. (2017). "mTOR Signaling in Growth, Metabolism, and Disease." Cell . PMID 28278478 (PubMed 28278478)
2. Raghuvanshi R et al. (2025). "Exploring the role of mTOR pathway in aging and age-related disorders." Front Pharmacol / Open Biology . PMID 40933955 (PubMed 40933955)
3. Hands JM et al. (2025). "What is the clinical evidence to support off-label rapamycin therapy in healthy adults?" Open Biology . PMID 40778880 (PubMed 40778880)
4. Kjøbsted R et al. (2018). "AMPK in skeletal muscle function and metabolism." FASEB J . PMID 29236611 (PubMed 29236611)
5. Wang X, Proud CG. (2006). "The mTOR pathway in the control of protein synthesis." Physiology . PMID 16990457 (PubMed 16990457)
6. PubMed 24847808 (PubMed 24847808)
7. PubMed 23341498 (PubMed 23341498)
8. Hardie DG, Steinberg GR. (2023). "New insights into activation and function of the AMPK." Nat Rev Mol Cell Biol . doi 10.1038/s41580-022-00547-x (DOI 10.1038/s41580-022-00547-x)
9. Marafie SK, Al-Mulla F, Abubaker J. (2024). "mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process." Int J Mol Sci 25(11):6141. doi 10.3390/ijms25116141 (DOI 10.3390/ijms25116141)
10. Peng W et al. (2024). "Clinical trials on rapamycin for anti-aging: a systematic review." GeroScience 46(2):1621-1633. PMID 37752251 (PubMed 37752251)
11. Burkewitz K et al. (2014). "AMPK at the Nexus of Energetics and Aging." Cell Metab . PMID 34838647 (PubMed 34838647)